| Literature DB >> 22826551 |
Albert Caramoy1, Sascha Fauser, Bernd Kirchhof.
Abstract
AIM: To study tissue remodelling and wound healing after retinal pigment epithelium (RPE) tears due to age-related macular degeneration.Entities:
Mesh:
Year: 2012 PMID: 22826551 PMCID: PMC3432490 DOI: 10.1136/bjophthalmol-2012-301750
Source DB: PubMed Journal: Br J Ophthalmol ISSN: 0007-1161 Impact factor: 4.638
A summary of demographic characteristics
| Patient no. | Eye | RPE tear grade | Age | BCVA (LogMAR) at first visit | BCVA (LogMAR) at last visit | Therapy prior to RPE tear (no.) | Time after RPE tears (d) | Total follow-up time (d) | FAF in RPE denuded area | HRDs | Subretinal mass at last follow-up |
| 1 | OS | 2 | 86 | 0.35 | 1.4 | Bevacizumab (1) | 1938 | 2092 | Dark | No | Yes |
| 2 | OD | 3 | 74 | 0.48 | 1.5 | Bevacizumab (1) | 1681 | 1861 | Hazy hyperfluorescent | Yes | No |
| 3 | OS | 3 | 90 | 1.30 | 1.05 | None | 882 | 1911 | Dark, patchy hyperfluorescent on the border | No | Yes |
| 4 | OD | 3 | 77 | 0.4 | 0.7 | Bevacizumab (4) | 325 | 329 | Dark | Yes | Yes |
| 5 | OS | 4 | 80 | 0.7 | 1.3 | Ranibizumab (3) | 330 | 425 | Dark | No | No |
| 6 | OD | 3 | 76 | 1.3 | NA | None | 222 | 1455 | Dark | Yes | Yes |
| 7 | OS | 4 | 73 | 0.45 | 1.4 | None | 212 | 215 | Dark | Yes | No |
| 8 | OD | 2 | 70 | 0.15 | 0.1 | None | 1041 | 1344 | Dark | Yes | No |
| 9 | OD | 3 | 72 | 0.45 | 0.5 | None | 372 | 1302 | Dark | Yes | Yes |
| OS | 4 | 0.5 | 0.7 | Ranibizumab (3), Bevacizumab (1) | 226 | 1302 | Patchy hyperfluorescent | Yes | No | ||
| 10 | OD | 1 | 82 | 0.7 | 1.5 | Ranibizumab (3) | 732 | 1671 | Dark | Yes | Yes |
| 11 | OD | 2 | 65 | 0.3 | 1.5 | Ranibizumab (2) | 52 | 168 | Dark | Yes | No |
| 12 | OD | 3 | 85 | 0.56 | NA | None | 53 | 54 | Dark | Yes | No |
| OS | 4 | 0.2 | NA | None | NA | 54 | Dark | Yes | No | ||
| 13 | OS | 2 | 80 | 0.55 | 0.58 | Ranibizumab (3) | 111 | 455 | Dark | No | No |
| 14 | OD | 4 | 75 | 0.6 | 0.2 | None | 1165 | 3405 | Patchy hyperfluorescent | Yes | No |
| 15 | OD | 4 | 78 | 0.45 | NA | Ranibizumab (2) | NA | NA | Dark | Yes | Yes |
| 16 | OS | 3 | 86 | 1 | 1 | None | 128 | 337 | Dark | Yes | Yes |
| 17 | OD | 2 | 68 | 0.4 | 0.4 | None | 104 | 1701 | Dark | Yes | Yes |
| 18 | OS | 2 | 62 | 0.3 | 0.3 | None | 109 | 946 | Patchy hyperfluorescent | Yes | Yes |
| 19 | OD | 3 | 81 | 1.30 | 1.7 | Ranibizumab (3) | 333 | 1262 | Dark | Yes | No |
| 20 | OD | 4 | 83 | 1.3 | NA | rtPA+SF6 (1), ranibizumab (1) | NA | 819 | Dark | No | No |
| 21 | OD | 1 | 79 | 0.60 | 0.1 | rtPA+SF6+bevacizumab (2) | 670 | 925 | Dark | Yes | Yes |
| 22 | OD | 4 | 81 | 0.7 | 1.5 | None | 593 | 1648 | Dark | Yes | No |
| OS | 4 | 0.26 | 1.3 | Ranibizumab (1) | 32 | 1648 | Dark | Yes | No | ||
| 23 | OD | 2 | 72 | 1 | 1.4 | Ranibizumab (3) | 77 | 231 | Dark | No | No |
| 24 | OS | 3 | 91 | 0.6 | 1.3 | Ranibizumab (3) | 895 | 992 | Dark | Yes | No |
| 25 | OS | 4 | 85 | 0.6 | NA | Ranibizumab (2) | NA | NA | Dark | Yes | Yes |
| 26 | OD | 1 | 71 | 0.6 | 0.6 | None | 110 | 2438 | Patchy hyperfluorescent | Yes | No |
| 27 | OS | 1 | 83 | 0.8 | 1 | None | 663 | 896 | Dark | Yes | Yes |
| 28 | OD | 4 | 61 | 0.3 | 0.4 | None | 317 | 709 | Dark | Yes | Yes |
| 29 | OD | 4 | 57 | 0.7 | 0.7 | None | 158 | 278 | Patchy hyperfluorescent | Yes | No |
| 30 | OS | 4 | 68 | 0.3 | 0.6 | Ranibizumab (3) | 1334 | 1996 | Dark | Yes | No |
| 31 | OD | 4 | 75 | 1.5 | 1.5 | rtPA+SF6 (1), ranibizumab (5), bevacizumab (2) | NA | 810 | Dark | Yes | Yes |
| 32 | OD | 1 | 67 | 1 | NA | None | NA | NA | Dark | Yes | No |
| 33 | OD | 4 | 72 | 0.2 | NA | None | NA | NA | Dark | Yes | No |
BCVA, best corrected visual acuity; d, days; FAF, fundus autofluorescence; HRDs, hyper-reflective dots; LogMAR, logarithm of the minimum angle of resolution; NA, not applicable; OD, the right eye; OS, the left eye; RPE, retinal pigment epithelium; rtPA, recombinant tissue plasminogen activator; SF6, sulphur hexafluoride 20%.
Figure 1A retinal pigment epithelium (RPE) tear 5 months after the acute event. Fundus autofluorescence (A) image showed patchy hyperfluorescent spots in the RPE denuded area. The corresponding spectral-domain optical coherence tomography (B) showed hyper-reflective dots (arrows). Shadowing effect posterior to the hyper-reflective dots can be seen.
Figure 2A retinal pigment epithelium (RPE) tear 1 year and 2 months after the acute event. Fundus autofluorescence (A) image of retinal pigment epithelium tear showed hyperfluorescent spots in the RPE denuded area. The corresponding spectral-domain optical coherence tomography image (B) showed hyper-reflective dots (arrow), indicating intraretinal RPE migration.
Figure 3A retinal pigment epithelium (RPE) tear 3 years after the acute event. Colour fundus photography (A) of RPE tear. The white star indicated the presence of intraretinal hard exudates, which appeared hypofluorescent in the corresponding fundus autofluorescence (B) image. The area between the two arrowheads (C) showed the enhanced choroidal hyper-reflectivity. A homogenous subretinal mass can also be seen. (D) The intraretinal hard exudates (star in A and B) are presented as a large hyper-reflective lesion with shadowing effect (white arrow). This figure is produced in colour in the online journal—please visit the website to view the colour figure.
Figure 4A case of self-healing retinal pigment epithelium (RPE) tear. The fundus autofluorescence (A) showed a small RPE defect, which corresponds to an area of enhanced choroidal hyper-reflectivity (B) (between arrowheads). Two and a half years after the RPE denuded area has been covered by a single RPE layer (C and D). The black star represents a small atrophy, used as an anatomical landmark, ensuring approximately the same level of SD-OCT measurements over time.